Edition:
India

MabVax Therapeutics Holdings Inc (MBVX.OQ)

MBVX.OQ on NASDAQ Stock Exchange Capital Market

0.86USD
12 Dec 2017
Change (% chg)

$-0.07 (-7.87%)
Prev Close
$0.93
Open
$0.90
Day's High
$0.92
Day's Low
$0.84
Volume
45,229
Avg. Vol
69,008
52-wk High
$3.97
52-wk Low
$0.43

Select another date:

Thu, Oct 26 2017

BRIEF-Mabvax to present three posters at AACR-NCI-EORTC Int'l conference

* Mabvax therapeutics to present three posters at the aacr-nci-eortc international conference on molecular targets and cancer therapeutics Source text for Eikon: Further company coverage:

BRIEF-MabVax Therapeutics files for resale of 9.7 mln shares‍​

* MabVax Therapeutics Holdings Inc - files for resale of 9.7 million shares of common stock of co by certain stockholders ‍​ Source text: (http://bit.ly/2gBSIB6) Further company coverage:

BRIEF-MabVax Therapeutics files for resale of up to 6.97 mln shares of co's common stock‍​

* MabVax Therapeutics Holdings Inc files for resale of up to 6.97 million shares of co's common stock‍​ by the selling stockholders - SEC filing‍​ Source text: [http://bit.ly/2x8TRa4] Further company coverage:

BRIEF-MabVax Therapeutics Holdings provides corporate overview and business outlook

* MabVax Therapeutics Holdings Inc provides corporate overview and business outlook

BRIEF-Mabvax Therapeutics starts patient enrollment in phase 1 trial for cancer drug MVT-1075

* Mabvax Therapeutics initiates patient enrollment in a phase 1 trial for MVT-1075, a new radioimmunotherapy treatment for advanced pancreatic, colon and lung cancers

BRIEF-MabVax stockholders approve remaining proposal at stockholders meeting

* MabVax Therapeutics Holdings - ‍resolution approved to implement, if necessary a reverse stock split of company's issued and outstanding common stock​

BRIEF-MabVax Therapeutics announces $1.25 mln registered direct offering

* MabVax Therapeutics Holdings announces $1.25 million registered direct offering

BRIEF-John Stetson discloses 5.64 percent passive stake in MabVax Therapeutics Holdings Inc

* John Stetson discloses 5.64 percent passive stake in MabVax Therapeutics Holdings Inc as of September 11, 2017- SEC filing‍​ Source text: (http://bit.ly/2fwmYNQ) Further company coverage:

BRIEF-Mabvax Therapeutics announces $2 mln registered direct offering

* Mabvax Therapeutics Holdings Inc announces $2.0 million registered direct offering

BRIEF-Mabvax Therapeutics engages Greenhill & co. as advisor for exploring strategic alternatives

* Mabvax Therapeutics engages Greenhill & Co. as advisor for exploring strategic alternatives

Select another date: